高级检索
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 综述 •
ENGLISH ABSTRACT
肺炎球菌疫苗对慢性阻塞性肺疾病的作用及其接种策略进展
吴奕星
张静
作者及单位信息
·
DOI： 10.3760/cma.j.cn112147-20210901-00616
Progress on the effectiveness of the pneumococcal vaccination in patients with chronic obstructive pulmonary disease
Wu Yixing
Zhang Jing
Authors Info & Affiliations
Wu Yixing
Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Zhang Jing
Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China
·
DOI： 10.3760/cma.j.cn112147-20210901-00616
792
163
0
0
7
1
PDF下载
APP内阅读
摘要

肺炎链球菌是导致慢性阻塞性肺疾病（简称慢阻肺）急性加重和合并社区获得性肺炎的重要致病原。肺炎球菌疫苗的接种可以降低慢阻肺患者肺炎的发生率，减少急性加重次数，具有显著的保护作用，但接种时机与复种、疫苗种类选择等尚存争议。本文主要对慢阻肺患者接种肺炎球菌疫苗的相关研究和接种策略进展进行综述。

ABSTRACT

Streptococcus pneumonia is an important pathogen leading to the acute exacerbation of chronic obstructive pulmonary disease (COPD) or COPD with pneumonia. Pneumococcal vaccination can reduce the incidence of community-acquired pneumonia, reduce the number of acute exacerbations, and have a significant protective effect on patients with COPD. However, there are still controversies about the timing of vaccination, revaccination, and the selection of vaccine types. This review mainly summarized the related researches and recommendations of pneumococcal vaccination in patients with COPD.

Zhang Jing, Email: mocdef.labiamxofgnijgnahzixuh
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

吴奕星,张静. 肺炎球菌疫苗对慢性阻塞性肺疾病的作用及其接种策略进展[J]. 中华结核和呼吸杂志,2022,45(04)：404-409.

DOI:10.3760/cma.j.cn112147-20210901-00616

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

慢性阻塞性肺疾病（简称慢阻肺），是一种常见的、以持续存在的呼吸系统症状和气流受限为特征的慢性疾病，位居全球第三大死亡原因 ［ 1 ］ 。由于持续暴露于空气污染、吸烟等慢阻肺的危险因素，以及世界人口老龄化，预计慢阻肺的患病率将在未来几十年内持续增加 ［ 2 ］ 。
慢阻肺患者气道黏膜的纤毛清除功能受损，介导细菌和病毒附着的黏附分子产生增加，以及治疗过程中吸入的糖皮质激素等因素，都会进一步增加肺部感染的风险。慢阻肺急性加重是慢阻肺患者死亡的重要因素，也是慢阻肺患者医疗费用的主要支出部分。呼吸道感染是慢阻肺急性加重的最常见原因，40%~60%的患者可从痰液中分离出细菌，细菌中的3种常见病原体分别是流感嗜血杆菌、卡他莫拉菌和肺炎链球菌 ［ 3 ］ 。同时，慢阻肺也是社区获得性肺炎（community acquired pneumonia，CAP）的危险因素之一，肺炎链球菌是其最重要的细菌致病原。本文就肺炎球菌疫苗对慢阻肺合并感染的预防作用以及接种策略综述如下。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016,388(10053):1545-1602. DOI: 10.1016/S0140-6736(16)31678-6 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Bafadhel M , McKenna S , Terry S ,et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers[J]. Am J Respir Crit Care Med, 2011,184(6):662-671. DOI: 10.1164/rccm.201104-0597OC .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Mackay AJ , Hurst JR . COPD exacerbations: causes, prevention, and treatment[J]. Med Clin North Am, 2012,96(4):789-809. DOI: 10.1016/j.mcna.2012.02.008 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Said MA , Johnson HL , Nonyane BA ,et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques[J]. PLoS One, 2013,8(4):e60273. DOI: 10.1371/journal.pone.0060273 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
江雁琼,伍慧妍,文艳琼. 慢阻肺急性加重期感染病原菌分布与机体免疫功能检测及其临床意义[J]. 中国病原生物学杂志, 2019,14(2):213-216. DOI: 10.13350/j.cjpb.190219 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
曾廷武,杜飞. 老年慢阻肺合并社区获得性肺炎患者的病原菌分布及药敏情况分析[J]. 当代医学, 2019,25(10):128-129. DOI: 10.3969/j.issn.1009-4393.2019.10.054 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and prevention of Chronic Obstructive Pulmonary Disease (2020 REPORT)[EB/OL].[ 2021-09-01]. http://www.goldcopd.org/.
返回引文位置Google Scholar
百度学术
万方数据
[8]
Suzuki K , Kondo K , Washio M ,et al. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study[J]. Hum Vaccin Immunother, 2019,15(9):2171-2177. DOI: 10.1080/21645515.2019.1584023 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Moberley S , Holden J , Tatham DP ,et al. Vaccines for preventing pneumococcal infection in adults[J]. Cochrane Database Syst Rev, 2013, (1):CD000422. DOI: 10.1002/14651858.CD000422.pub3 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Walters JA , Tang JN , Poole P ,et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2017,1:CD001390. DOI: 10.1002/14651858.CD001390.pub4 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Alfageme I , Vazquez R , Reyes N ,et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD[J]. Thorax, 2006,61(3):189-195. DOI: 10.1136/thx.2005.043323 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Fekete M , Pako J , Nemeth AN ,et al. Prevalence of influenza and pneumococcal vaccination in chronic obstructive pulmonary disease patients in association with the occurrence of acute exacerbations[J]. J Thorac Dis, 2020,12(8):4233-4242. DOI: 10.21037/jtd-20-814 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
荣恒漠,杨炯. 肺炎疫苗应用于支气管扩张症及慢性阻塞性肺疾病患者的效果[J]. 武汉大学学报(医学版), 2017,38(1):90-95.
返回引文位置Google Scholar
百度学术
万方数据
[14]
徐娜,罗坤,李春玉. 23价肺炎球菌多糖疫苗对慢性阻塞性肺疾病影响的meta分析[J]. 职业与健康, 2020,36(1):114-118.
返回引文位置Google Scholar
百度学术
万方数据
[15]
周志强,曲建卫,咸本松,等. 慢性阻塞性肺疾病患者接种肺炎球菌疫苗疗效的Meta分析[J]. 中华全科医学, 2018,16(9):1562-1565,1574. DOI: 10.16766/j.cnki.issn.1674-4152-000425 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Trofimov VI , Shaporova NL , Marchenko VN ,et al. Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity[J]. Zh Mikrobiol Epidemiol Immunobiol, 2010, (4):41-44.
返回引文位置Google Scholar
百度学术
万方数据
[17]
温莹,何柳,翟屹,等. 流行性感冒病毒裂解疫苗和23价肺炎球菌多糖疫苗改善老年人慢性阻塞性肺疾病的社区干预试验[J]. 中华流行病学杂志, 2018,39(6):792-798. DOI: 10.3760/cma.j.issn.0254-6450.2018.06.019 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Bonten MJ , Huijts SM , Bolkenbaas M ,et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults[J]. N Engl J Med, 2015,372(12):1114-1125. DOI: 10.1056/NEJMoa1408544 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Suaya JA , Jiang Q , Scott DA ,et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults[J]. Vaccine, 2018,36(11):1477-1483. DOI: 10.1016/j.vaccine.2018.01.049 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
McLaughlin JM , Jiang Q , Isturiz RE ,et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design[J]. Clin Infect Dis, 2018,67(10):1498-1506. DOI: 10.1093/cid/ciy312 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Mantero M , Aliberti S , Azzari C ,et al. Role of Streptococcus pneumoniae infection in chronic obstructive pulmonary disease patients in Italy[J]. Ther Adv Respir Dis, 2017,11(10):403-407. DOI: 10.1177/1753465817728479 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Ignatova GL , Antonov VN . Impact of vaccination on the course of bronchial and systemic inflammation in patients with COPD and CHD[J]. Ter Arkh, 2017,89(3):29-33. DOI: 10.17116/terarkh201789329-33 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Figueira-Gonçalves JM , Bethencourt-Martín N , Pérez-Méndez LI ,et al. Impact of 13-valent pneumococal conjugate polysaccharide vaccination in exacerbations rate of COPD patients with moderate to severe obstruction[J]. Rev Esp Quimioter, 2017,30(4):269-275.
返回引文位置Google Scholar
百度学术
万方数据
[24]
Dransfield MT , Harnden S , Burton RL ,et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease[J]. Clin Infect Dis, 2012,55(5):e35-44. DOI: 10.1093/cid/cis513 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Dransfield MT , Nahm MH , Han MK ,et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2009,180(6):499-505. DOI: 10.1164/rccm.200903-0488OC .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Jackson LA , Gurtman A , Rice K ,et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine[J]. Vaccine, 2013,31(35):3585-3593. DOI: 10.1016/j.vaccine.2013.05.010 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Jackson LA , Gurtman A , van Cleeff M ,et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults[J]. Vaccine, 2013,31(35):3577-3584. DOI: 10.1016/j.vaccine.2013.04.085 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Berical AC , Harris D , Dela Cruz CS ,et al. Pneumococcal Vaccination Strategies. An Update and Perspective[J]. Ann Am Thorac Soc, 2016,13(6):933-944. DOI: 10.1513/AnnalsATS.201511-778FR .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Musher DM . Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?[J]. Clin Infect Dis, 2012,55(2):265-267. DOI: 10.1093/cid/cis364 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper[J]. Wkly Epidemiol Rec, 2019,94(8):85-103.
返回引文位置Google Scholar
百度学术
万方数据
[31]
Matanock A , Lee G , Gierke R ,et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019,68(46):1069-1075. DOI: 10.15585/mmwr.mm6846a5 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Tomczyk S , Bennett NM , Stoecker C ,et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Morb Mortal Wkly Rep, 2014,63(37):822-825.
返回引文位置Google Scholar
百度学术
万方数据
[33]
Shapiro ED , Berg AT , Austrian R ,et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine[J]. N Engl J Med, 1991,325(21):1453-1460. DOI: 10.1056/NEJM199111213252101 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper[J]. Wkly Epidemiol Rec, 2008,83(42):373-384.
返回引文位置Google Scholar
百度学术
万方数据
[35]
Jackson LA , Gurtman A , van Cleeff M ,et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older[J]. Vaccine, 2013,31(35):3594-3602. DOI: 10.1016/j.vaccine.2013.04.084 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
Greenberg RN , Gurtman A , Frenck RW ,et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age[J]. Vaccine, 2014,32(20):2364-2374. DOI: 10.1016/j.vaccine.2014.02.002 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
Garmpi A , Damaskos C , Garmpis N ,et al. Pneumococcal Vaccination Strategies Among HIV-infected Adult Patients: A Review of the Literature[J]. In Vivo, 2019,33(5):1425-1430. DOI: 10.21873/invivo.11620 .
返回引文位置Google Scholar
百度学术
万方数据
[38]
Breiman RF , Keller DW , Phelan MA ,et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients[J]. Arch Intern Med, 2000,160(17):2633-2638. DOI: 10.1001/archinte.160.17.2633 .
返回引文位置Google Scholar
百度学术
万方数据
[39]
French N , Nakiyingi J , Carpenter LM ,et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial[J]. Lancet, 2000,355(9221):2106-2111. DOI: 10.1016/s0140-6736(00)02377-1 .
返回引文位置Google Scholar
百度学术
万方数据
[40]
Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)[J]. MMWR Morb Mortal Wkly Rep, 2012,61(40):816-819.
返回引文位置Google Scholar
百度学术
万方数据
[41]
Thompson AR , Klein NP , Downey HJ ,et al. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial[J]. Hum Vaccin Immunother, 2019,15(2):444-451. DOI: 10.1080/21645515.2018.1533777 .
返回引文位置Google Scholar
百度学术
万方数据
[42]
Schwarz TF , Flamaing J , Rümke HC ,et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years[J]. Vaccine, 2011,29(32):5195-5202. DOI: 10.1016/j.vaccine.2011.05.031 .
返回引文位置Google Scholar
百度学术
万方数据
[43]
Ignatova GL , Antonov VN , Blinova EV . Analysis of the effectiveness of joint or sequential vaccination with pneumococcal and influenza vaccines in patients with chronic obstructive pulmonary disease[J]. Ter Arkh, 2019,91(8):12-17. DOI: 10.26442/00403660.2019.08.000205 .
返回引文位置Google Scholar
百度学术
万方数据
[44]
李松明,张继先,孙震. 慢性阻塞性肺疾病急性加重患者接种流感疫苗和肺炎疫苗效果观察[J]. 预防医学, 2017,29(05):485-486. DOI: 10.19485/j.cnki.issn1007-0931.2017.05.014 .
返回引文位置Google Scholar
百度学术
万方数据
[45]
Kim DK , Hunter P . Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older-United States, 2019[J]. MMWR Morb Mortal Wkly Rep, 2019,68(5):115-118. DOI: 10.15585/mmwr.mm6805a5 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
张静，Email： mocdef.labiamxofgnijgnahzixuh
B

吴奕星, 张静. 肺炎球菌疫苗对慢性阻塞性肺疾病的作用及其接种策略进展[J]. 中华结核和呼吸杂志, 2022, 45(4): 404-409. DOI: 10.3760/cma.j.cn112147-20210901-00616.

C
所有作者声明无利益冲突
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大